

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0759**
Inventors: **Monia et al.**
Serial No.: **Not yet assigned**
Filing Date: **Herewith**
Examiner: **Not yet assigned**
Group Art Unit: **Not yet assigned**
Title: **Antisense Modulation of Focal Adhesion
Kinase Expression**

"Express Mail" Label No. **EL976562779US**
Date of Deposit - **August 22, 2003**

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop Sequence P. O. Box
1450, Alexandria, VA 22313-1450.

By *Jane Massey Licata*
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/757,100 filed January 9, 2001 and 09/377,310 filed August 19, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 12-1086. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: August 22, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0759	Serial No. Not yet assigned
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Monia et al.	
		Filing Date Herewith	Group Not yet assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Lou, et al., "In Vivo Gene Transfer and Overexpression of Focal Adhesion Kinase (p125 FAK) Mediated by Recombinant Adenovirus-Induced Tendon Adhesion Formation and Epitenon Cell Change", <i>J. Orthopaedic Res.</i> 1997, 15, 911-918	
	AB	Naruse, et al., "Pp125 ^{FAK} is required for stretch dependent morphological response of endothelial cells", <i>Oncogene</i> 1998, 17, 445-463	
	AC	Shibata, K., et al., "Both Focal Adhesion Kinase and c-Ras Are Required for the Enhanced Matrix Metalloproteinase 9 Secretion by Fibronectin in Ovarian Cancer Cells ¹ ", <i>Cancer Res.</i> , 1998, 5, 900-903	
	AD	Sonoda, et al., "A Suppressive Role of p125FAK Protein Tyrosine Kinase in Hydrogen Peroxide-Induced Apoptosis of T98G Cells", <i>Biochem. Biophys. Res. Comm.</i> , 1997, 241, 769-774	
	AE	Tanaka et al., "Possible Involvement of Focal Adhesion Kinase, p125 ^{FAK} , in Osteoclastic Bone Resorption", <i>J. Cell. Biochem.</i> 1995, 58, 424-435	
	AF	Takeuchi, et al., "Differentiation and Transforming Growth Factor- β Receptor Down-regulation by Collagen- $\alpha 2 \beta 1$ Integrin Interaction Is Mediated by Focal Adhesion Kinase and Its Downstream Signals in Murine Osteoblastic Cells", <i>J. Biol. Chem.</i> , 1997, 272, 29309-29316	
	AG	Xu, et al., "Attenuation of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells ¹ ", <i>Cell Growth Diff.</i> , 1996, 7, 413-418	
EXAMINER		DATE CONSIDERED	